Hospital & Healthcare Services · Founded 2008 · www.yatharthhospitals.com · BSE 543950 · NSE YATHARTH · ISIN INE0JO301016
No Notes Added Yet
Business
Yatharth Hospital & Trauma Care Services Ltd. is an India-based company operating multi-specialty tertiary care hospitals. The company provides a comprehensive range of healthcare services, including inpatient and outpatient consultations, emergency care, advanced surgical procedures, diagnostic services, and critical care across various medical disciplines such. Its core business model involves owning and operating hospitals and generating revenue through fees charged for medical services provided to patients, including direct payments, corporate tie-ups, and health insurance reimbursements.
Revenue Mix
While specific revenue contribution percentages are not provided, the company's primary revenue streams typically originate from:
Inpatient Services: This segment usually constitutes the largest portion of revenue for multi-specialty hospitals, encompassing room charges, surgical fees, consultation fees, and procedures for admitted patients.
Outpatient Services: Includes consultations, minor procedures, and diagnostic tests performed on an outpatient basis.
Ancillary Services: Comprises revenues from pharmacies, pathology, radiology, and other support services.
Given its focus on tertiary care and trauma services, a significant portion of its revenue is likely derived from complex surgical procedures and critical care.
Industry
The Indian healthcare industry is characterized by strong growth driven by increasing disposable incomes, rising health awareness, and growing insurance penetration. It is a fragmented market, but with increasing consolidation among organized private players. Yatharth Hospital is positioned as a regional multi-specialty hospital chain, primarily serving the Delhi NCR region and Uttar Pradesh. It aims to provide quality, accessible, and affordable healthcare, catering to the growing middle-class population that seeks advanced medical facilities beyond public healthcare. It competes with both large national hospital chains and smaller, localized healthcare providers.
MOAT
Yatharth's competitive advantages are likely to include:
Brand Reputation & Trust: Building patient trust and a strong local brand in its operational geographies over time, particularly for specific specialties or emergency services.
Doctor Relationships: Ability to attract and retain experienced medical professionals and specialists, which is crucial for patient flow and quality of care.
High Capital Intensity: The significant upfront capital investment required to set up and equip multi-specialty hospitals acts as a barrier to entry for new competitors.
Localized Network Effect: Establishing a presence and referral network within its target regions.
Growth Drivers
Key factors that can drive Yatharth Hospital's growth over the next 3-5 years include:
Rising Healthcare Demand: India's large and growing population, increasing life expectancy, and higher prevalence of chronic diseases will continue to drive demand for quality healthcare services.
Increased Health Insurance Penetration: Growing adoption of public and private health insurance schemes makes quality healthcare more accessible and affordable for a wider population.
Capacity Expansion: Strategic expansion into new geographies or increasing bed capacities and service offerings in existing hospitals.
Medical Tourism: Potential to attract patients from neighboring regions or countries seeking quality healthcare at competitive costs.
Focus on Specialties: Expanding into high-demand and high-margin medical specialties.
Risks
Key business risks for Yatharth Hospital include:
Regulatory & Pricing Risks: Government interventions in healthcare pricing (e.g., price caps on procedures, medicines, or medical devices) could impact profitability.
Intense Competition: The hospital sector is highly competitive, facing pressure from established national chains, regional players, and single-specialty hospitals.
Doctor Attrition & Retention: High reliance on skilled medical professionals means losing key doctors can significantly impact patient flow and reputation.
High Capital Expenditure & Debt: Expansion plans often require significant capital investment, which, if funded by debt, can increase financial leverage and interest costs.
Operational Risks: Risks associated with medical errors, equipment failures, litigation, and maintaining high-quality patient care standards.
Economic Downturn: Could lead to reduced discretionary spending on elective procedures and impact patient volumes.
Management & Ownership
Yatharth Hospital is typically promoter-led, with the founding family or individuals playing a significant role in its strategic direction and operations. Promoters usually maintain a substantial ownership stake post-listing, aligning their interests with the company's long-term growth. The management team is expected to be comprised of professionals with experience in hospital administration, finance, and medical operations, focused on operational efficiency, clinical excellence, and strategic expansion.
Outlook
Yatharth Hospital operates in a sector with significant tailwinds from India's growing healthcare needs and increasing affordability of private medical services. The company's focus on multi-specialty tertiary care in its chosen geographies positions it to capitalize on this demand. However, success will depend on its ability to navigate an increasingly competitive and regulatory-sensitive environment. Efficient execution of expansion plans, maintaining high standards of medical care, attracting and retaining top medical talent, and prudent financial management will be critical to its sustained growth and profitability. The balance between aggressive expansion and maintaining operational efficiency will define its trajectory in the coming years.
Price goes above X
Price falls below X
PE goes above X
PE falls below X
| #(Fig in Cr.) | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 178 | 212 | 218 | 219 | 233 | 259 | 279 | 320 | 342 | 393 |
| Other Income | 6 | 4 | 3 | 4 | 4 | 8 | 9 | 8 | 7 | 4 |
| Total Income | 183 | 215 | 221 | 223 | 237 | 267 | 289 | 328 | 349 | 397 |
| Total Expenditure | 131 | 158 | 163 | 164 | 175 | 193 | 215 | 246 | 262 | 301 |
| Operating Profit | 52 | 57 | 58 | 59 | 62 | 74 | 74 | 82 | 87 | 96 |
| Interest | 0 | 3 | 2 | 2 | 1 | 0 | 0 | 1 | 5 | 7 |
| Depreciation | 8 | 11 | 16 | 17 | 13 | 15 | 19 | 24 | 30 | 28 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 44 | 43 | 40 | 40 | 49 | 59 | 55 | 57 | 52 | 61 |
| Provision for Tax | 6 | 13 | 9 | 10 | 10 | 17 | 14 | 14 | 7 | 16 |
| Profit After Tax | 38 | 30 | 31 | 30 | 39 | 42 | 41 | 43 | 45 | 45 |
| Adjustments | -0 | 0 | 0 | 0 | -0 | -0 | -0 | 2 | 3 | 2 |
| Profit After Adjustments | 38 | 30 | 31 | 30 | 39 | 42 | 41 | 45 | 48 | 47 |
| Adjusted Earnings Per Share | 4.5 | 3.5 | 3.6 | 3.2 | 4 | 4.4 | 4.3 | 4.7 | 4.9 | 4.9 |
| #(Fig in Cr.) | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 102 | 146 | 229 | 401 | 520 | 671 | 886 | 1207 | 1334 |
| Other Income | 0 | 0 | 1 | 2 | 3 | 16 | 11 | 26 | 28 |
| Total Income | 102 | 146 | 229 | 403 | 523 | 686 | 897 | 1233 | 1363 |
| Total Expenditure | 82 | 108 | 161 | 289 | 385 | 489 | 655 | 903 | 1024 |
| Operating Profit | 20 | 39 | 69 | 114 | 138 | 198 | 241 | 330 | 339 |
| Interest | 7 | 20 | 20 | 23 | 23 | 11 | 13 | 19 | 13 |
| Depreciation | 8 | 21 | 21 | 28 | 28 | 29 | 57 | 88 | 101 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 5 | -2 | 28 | 63 | 88 | 157 | 172 | 224 | 225 |
| Provision for Tax | 1 | -0 | 9 | 19 | 22 | 42 | 41 | 53 | 51 |
| Profit After Tax | 4 | -2 | 20 | 44 | 66 | 114 | 131 | 170 | 174 |
| Adjustments | -0 | 1 | -1 | 0 | 0 | 0 | -0 | 5 | 7 |
| Profit After Adjustments | 4 | -1 | 18 | 44 | 66 | 114 | 131 | 175 | 181 |
| Adjusted Earnings Per Share | 0.6 | -0.2 | 2.8 | 6.7 | 10 | 13.3 | 13.5 | 18.2 | 18.8 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 36% | 32% | 39% | 0% |
| Operating Profit CAGR | 37% | 34% | 37% | 0% |
| PAT CAGR | 30% | 37% | 53% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | 38% | 39% | NA% | NA% |
| ROE Average | 10% | 14% | 27% | 21% |
| ROCE Average | 13% | 17% | 21% | 17% |
| #(Fig in Cr.) | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Shareholder's Funds | 56 | 54 | 72 | 117 | 183 | 874 | 1605 | 1781 |
| Minority's Interest | 3 | 8 | 8 | 0 | 0 | 0 | 32 | 27 |
| Borrowings | 146 | 157 | 164 | 207 | 201 | 75 | 1 | 227 |
| Other Non-Current Liabilities | 10 | 8 | 9 | -1 | -5 | -8 | -10 | 37 |
| Total Current Liabilities | 42 | 60 | 55 | 97 | 100 | 67 | 85 | 184 |
| Total Liabilities | 257 | 287 | 309 | 421 | 478 | 1009 | 1713 | 2255 |
| Fixed Assets | 164 | 189 | 251 | 303 | 299 | 442 | 605 | 1250 |
| Other Non-Current Assets | 69 | 69 | 9 | 8 | 3 | 57 | 252 | 293 |
| Total Current Assets | 24 | 29 | 49 | 109 | 176 | 510 | 856 | 712 |
| Total Assets | 257 | 287 | 309 | 421 | 478 | 1009 | 1713 | 2255 |
| #(Fig in Cr.) | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 13 | 0 | 2 | 5 | 12 | 37 | 108 | 360 |
| Cash Flow from Operating Activities | 17 | 39 | 44 | 60 | 64 | -3 | 131 | 205 |
| Cash Flow from Investing Activities | -78 | -43 | -21 | -52 | -20 | -226 | -388 | -598 |
| Cash Flow from Financing Activities | 47 | 5 | -19 | -1 | -18 | 304 | 509 | 254 |
| Net Cash Inflow / Outflow | -13 | 1 | 3 | 7 | 26 | 75 | 253 | -140 |
| Closing Cash & Cash Equivalent | 0 | 2 | 5 | 12 | 37 | 113 | 360 | 220 |
| # | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | 0.61 | -0.2 | 2.77 | 6.74 | 10.04 | 13.33 | 13.55 | 18.2 |
| CEPS(Rs) | 1.89 | 2.94 | 6.13 | 10.99 | 14.24 | 16.75 | 19.48 | 26.79 |
| DPS(Rs) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Book NAV/Share(Rs) | 8.49 | 8.29 | 11.06 | 17.84 | 27.93 | 101.84 | 166.62 | 184.79 |
| Core EBITDA Margin(%) | 19.68 | 26.32 | 29.76 | 27.93 | 25.98 | 27.14 | 26.01 | 25.21 |
| EBIT Margin(%) | 11.68 | 11.84 | 21 | 21.39 | 21.23 | 25.1 | 20.8 | 20.08 |
| Pre Tax Margin(%) | 4.93 | -1.7 | 12.3 | 15.74 | 16.85 | 23.39 | 19.39 | 18.52 |
| PAT Margin (%) | 3.91 | -1.41 | 8.57 | 11.01 | 12.64 | 17.07 | 14.74 | 14.11 |
| Cash Profit Margin (%) | 12.14 | 13.17 | 17.56 | 17.97 | 17.93 | 21.44 | 21.2 | 21.38 |
| ROA(%) | 1.55 | -0.76 | 6.57 | 12.11 | 14.64 | 15.4 | 9.59 | 8.58 |
| ROE(%) | 7.15 | -3.74 | 30.91 | 46.65 | 43.87 | 21.65 | 10.53 | 10.06 |
| ROCE(%) | 5.4 | 7.53 | 19.3 | 27.07 | 26.88 | 23.97 | 14.35 | 13.3 |
| Receivable days | 42.75 | 36.03 | 42.83 | 55.67 | 67.76 | 91.08 | 108.91 | 102.24 |
| Inventory Days | 8.1 | 6.4 | 4.99 | 3.91 | 3.95 | 3.87 | 5.99 | 6.29 |
| Payable days | 489.53 | 331.95 | 165.15 | 134.8 | 153.39 | 138.44 | 60.31 | 108.23 |
| PER(x) | 0 | 0 | 0 | 0 | 0 | 31.3 | 31.35 | 33.91 |
| Price/Book(x) | 0 | 0 | 0 | 0 | 0 | 4.1 | 2.55 | 3.34 |
| Dividend Yield(%) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EV/Net Sales(x) | 1.77 | 1.36 | 0.86 | 0.78 | 0.56 | 5.11 | 4.13 | 4.92 |
| EV/Core EBITDA(x) | 8.9 | 5.16 | 2.88 | 2.74 | 2.11 | 17.34 | 15.14 | 17.98 |
| Net Sales Growth(%) | 0 | 43.41 | 56.59 | 75.33 | 29.77 | 28.88 | 32.07 | 36.31 |
| EBIT Growth(%) | 0 | 45.33 | 177.74 | 78.6 | 28.81 | 52.37 | 9.46 | 31.54 |
| PAT Growth(%) | 0 | -151.62 | 1054.12 | 125.45 | 48.92 | 74.06 | 14.04 | 30.45 |
| EPS Growth(%) | 0 | -132.72 | 1495.67 | 143.18 | 48.93 | 32.83 | 1.61 | 34.34 |
| Debt/Equity(x) | 2.96 | 3.4 | 2.57 | 2.21 | 1.44 | 0.1 | 0 | 0.14 |
| Current Ratio(x) | 0.57 | 0.48 | 0.9 | 1.13 | 1.77 | 7.59 | 10.12 | 3.87 |
| Quick Ratio(x) | 0.51 | 0.43 | 0.84 | 1.07 | 1.71 | 7.47 | 9.87 | 3.76 |
| Interest Cover(x) | 1.73 | 0.87 | 2.41 | 3.79 | 4.85 | 14.66 | 14.74 | 12.89 |
| Total Debt/Mcap(x) | 0 | 0 | 0 | 0 | 0 | 0.02 | 0 | 0.04 |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 66.54 | 66.54 | 66.54 | 61.44 | 61.64 | 61.64 | 61.64 | 55.8 | 55.8 | 55.8 |
| FII | 3.99 | 4.89 | 6.28 | 9.78 | 4.45 | 4.34 | 6.5 | 6.18 | 5.25 | 5.62 |
| DII | 9.3 | 9.4 | 6.98 | 11.25 | 12.05 | 12.07 | 8.69 | 10.78 | 11.17 | 10.84 |
| Public | 20.16 | 19.16 | 20.2 | 17.53 | 21.85 | 21.95 | 23.17 | 27.24 | 27.79 | 27.74 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 5.71 | 5.71 | 5.71 | 5.92 | 5.94 | 5.94 | 5.94 | 5.38 | 5.38 | 5.38 |
| FII | 0.34 | 0.42 | 0.54 | 0.94 | 0.43 | 0.42 | 0.63 | 0.6 | 0.51 | 0.54 |
| DII | 0.8 | 0.81 | 0.6 | 1.08 | 1.16 | 1.16 | 0.84 | 1.04 | 1.08 | 1.04 |
| Public | 1.73 | 1.65 | 1.73 | 1.69 | 2.11 | 2.11 | 2.23 | 2.62 | 2.68 | 2.67 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8.59 | 8.59 | 8.59 | 9.64 | 9.64 | 9.64 | 9.64 | 9.64 | 9.64 | 9.64 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | +36% | +32% | +39% | — |
| Operating Profit CAGR | +37% | +34% | +37% | — |
| PAT CAGR | +30% | +37% | +53% | — |
| Share Price CAGR | +38% | +39% | — | — |
| ROE Average | +10% | +14% | +27% | +21% |
| ROCE Average | +13% | +17% | +21% | +17% |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 66.54 | 66.54 | 66.54 | 61.44 | 61.64 | 61.64 | 61.64 | 55.8 | 55.8 | 55.8 |
| FII | 3.99 | 4.89 | 6.28 | 9.78 | 4.45 | 4.34 | 6.5 | 6.18 | 5.25 | 5.62 |
| DII | 9.3 | 9.4 | 6.98 | 11.25 | 12.05 | 12.07 | 8.69 | 10.78 | 11.17 | 10.84 |
| Public | 20.16 | 19.16 | 20.2 | 17.53 | 21.85 | 21.95 | 23.17 | 27.24 | 27.79 | 27.74 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 5.71 | 5.71 | 5.71 | 5.92 | 5.94 | 5.94 | 5.94 | 5.38 | 5.38 | 5.38 |
| FII | 0.34 | 0.42 | 0.54 | 0.94 | 0.43 | 0.42 | 0.63 | 0.6 | 0.51 | 0.54 |
| DII | 0.8 | 0.81 | 0.6 | 1.08 | 1.16 | 1.16 | 0.84 | 1.04 | 1.08 | 1.04 |
| Public | 1.73 | 1.65 | 1.73 | 1.69 | 2.11 | 2.11 | 2.23 | 2.62 | 2.68 | 2.67 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8.59 | 8.59 | 8.59 | 9.64 | 9.64 | 9.64 | 9.64 | 9.64 | 9.64 | 9.64 |
* The pros and cons are machine generated.
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.
Your relationship manager will connect with you shortly.